Mineralys Therapeutics, Inc. (MLYS) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MLYS Revenue Growth
MLYS Revenue Analysis (2020–2025)
As of May 7, 2026, Mineralys Therapeutics, Inc. (MLYS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, MLYS's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including CORT (+12.2% YoY), INVA (+13.6% YoY), and NKTR (-32.8% YoY). Compare MLYS vs CORT →
MLYS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MLYSCurrent | $0 | - | - | - | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 NKTR | $55M | -32.8% | -18.4% | -253.7% | |
 MNKD | $349M | +21.2% | +39.9% | 11.1% |
MLYS Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-59,000 | - | $-170,604,000 | - |
| 2024 | $0 | - | $0 | - | $-192,403,000 | - |
| 2023 | $0 | - | $0 | - | $-84,657,000 | - |
| 2022 | $0 | - | $0 | - | $-31,479,000 | - |
| 2021 | $0 | - | $0 | - | $-18,725,000 | - |
| 2020 | $0 | - | $0 | - | $-2,943,000 | - |
See MLYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLYS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMLYS — Frequently Asked Questions
Quick answers to the most common questions about buying MLYS stock.
Is MLYS's revenue growth accelerating or slowing?
MLYS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MLYS's long-term revenue growth rate?
Mineralys Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MLYS's revenue distributed by segment?
MLYS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.